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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To examine the effects of anabolic steroids on functional outcome (independence, mobility and activities of daily living) after surgical
treatment of hip fracture in older people.
The following main comparisons are intended, set in the context of usual or conventional care:
• Anabolic steroids versus no or placebo intervention
• Anabolic steroids with other intervention (either nutrition or exercises or both) versus no or placebo intervention
B A C K G R O U N D
Description of the condition
Fracture of the proximal femur (known widely as hip fracture) is a
common cause of morbidity and mortality in the elderly popula-
tion. Age specific incidence curves for women and formen showed
similar patterns of increase in risk with age, with risks approxi-
mately doubling every five years after the age of 50 (Farmer 1984).
By the age of 90, one third of women and one sixth of men will
have sustained a hip fracture (Riggs 1986). Surgical management
is the mainstay of the treatment for hip fracture. This is generally
followed by inpatient rehabilitation, with or without extension
to an outpatient rehabilitation program. Despite treatment, func-
tional recovery after hip fracture is often incomplete, with many
patients who were walking independently before their hip frac-
ture losing their independence (Koval 1996; Lyons 1997). This
negatively impacts on their health-related quality of life (Adachi
2001). By six to 12 months after a hip fracture, between 22% and
75% of people have not recovered their pre-fracture ambulatory
or functional status (Cummings 1988; Koval 1995). Patients sus-
taining hip fracture require extensive health system resources (Ray
1997), and many patients require continued supportive services.
After their initial treatment, people who have had a hip fracture
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are at high risk for re-hospitalisation (Wolinsky 1997), refracture
(Johnell 1985) and institutionalisation (Bonar 1990; Rosell 2003).
With the rise in life expectancy, the prevalence of hip fracture is
expected to rise (Gullberg 1997).
Description of the intervention
Following surgical treatment of hip fracture, a wide range of ther-
apies are used to assist functional recovery (SIGN 2009). Some of
these have specific goals such as restoration of mobility, and inde-
pendence in basic activities of daily living. This review focusses on
the use of anabolic steroids for restoring function after hip fracture
surgery.
Anabolic steroids are a group of synthetic hormones, related to the
male hormone testosterone, that promote the storage of protein
and the growth of tissue (anabolism) (Dorland 2007). Their use
has been demonstrated to have a positive effect in the treatment of
diverse clinical conditions, including the treatment of anaemia in
renal disease patients (Navarro 2002; Teruel 1996), osteoporosis
(specifically bone density), cachexia in people with chronic illness
(Johns 2009), and improving muscle mass and strength in older
people (Snyder 1999). Women show an age-related decline in en-
dogenous androgen levels which might influence the development
of osteoporosis (Zofkova 2000). A double-blind study showed bet-
ter mobility and less pain in people with vertebral fractures af-
ter treatment with anabolic steroids compared with alphacalcidol
(Lyritis 1994).
Anabolic steroids come in different preparations, which can be
given various ways (e.g. orally, skin patches, intramuscular injec-
tions), start at different times (prior to surgery, or at any stage of
recovery after hip fracture surgery) and can be administered for
different lengths of time.
How the intervention might work
Patients with hip fractures are often elderly, frail and undernour-
ished (Bachrach-Lindström 2000; Lumbers 2001). They may un-
dergo a catabolic state (Patterson 1992), which leads to chronic
muscle wasting and reduced muscle strength. This can affect mo-
bility and result in falls. Loss of muscle mass and lean body weight
contribute to generalised weakness, an impaired immune response
and slower wound healing. Anabolic steroids have shown some
benefit in conditions with increased catabolic rates such as burns,
chronic obstructive airway disease and acquired immune defi-
ciency syndrome (AIDS) (Berger 1996).
There is also good reason to combine the use of anabolic steroids
with nutritional supplementation. Protein energymalnutrition oc-
curs in 30% to 50% of people who sustain a hip fracture (Lumbers
1996; Ponzer 1999). Postoperative hip fracture rehabilitation is fa-
cilitated by improving the nutritional intake of the patient (Delmi
1990). A Cochrane review concluded that some evidence exists
for the beneficial effects of nutritional supplementation after hip
fracture, although adherence can be a problem (Avenell 2006).
Chapman 2009 provides some evidence that combining testos-
terone and nutritional supplementation for undernourished older
people reduces both the number of people hospitalised and the
duration of hospital admissions.
Adverse effects, often dose related, from anabolic steroids include
growth of facial hair in women, hair loss, acne, oedema and liver
damage.
Why it is important to do this review
Hip fractures are a major cause of hospital admission. Despite
advances in surgical treatment these fractures continue to have a
large impact on older people and society because they result in high
rates of disability and institutionalisation. Anabolic steroids may
have a role in improving outcomes and restoring a greater degree
of independence in these patients. It is important to assess the
evidence for the use of these drugs in this predominantly elderly
and frail population.
O B J E C T I V E S
To examine the effects of anabolic steroids on functional outcome
(independence,mobility and activities of daily living) after surgical
treatment of hip fracture in older people.
The following main comparisons are intended, set in the context
of usual or conventional care:
• Anabolic steroids versus no or placebo intervention
• Anabolic steroids with other intervention (either nutrition
or exercises or both) versus no or placebo intervention
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of anabolic steroids treatment fol-
lowing surgical treatment of hip fracture. Trials that used a quasi-
randomisation (e.g. allocation by date of birth or hospital record
number) or cluster (e.g. by hospital ward) randomisation will be
included as will trials that were not analysed on an intention-to-
treat basis.
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Types of participants
The main study population will be older people with any type of
hip fracture that has been surgically treated. It is anticipated that
a large proportion of these patients will be older than 65 years of
age. Trials that include younger participants will be included if
the mean age, minus one standard deviation, is greater than 65
years. Participants younger than 65 years, or with multitrauma
or pathological fractures, will be included as long as they make
up less than 25% of the total sample size and there was adequate
randomisation of these participants to intervention and control
groups.
Types of interventions
The intervention assessed will be anabolic steroids, which come
in different preparations and can be given enterally (orally, na-
sogastric or via percutaneous gastrostomy tubes) or parenterally
(via transdermal, intramuscular routes, etc). The intervention can
start prior to surgery, or at any stage of recovery after hip frac-
ture surgery, but interventions that are pre-surgical only will be
excluded. The duration of administration may vary and can last
until the end of the rehabilitation phase. The administration of
anabolic steroids will be compared with the provision of no in-
tervention or a placebo intervention. It is envisaged that usual or
conventional care will be provided to all trial participants. Stud-
ies that compare the effects of anabolic steroids, alone or in con-
junction with other interventions, namely nutrition or exercise or
both, versus no intervention or the administration of a placebo
will be included.
The following comparisons are intended, set in the context of
usual or conventional care:
1. Anabolic steroids versus no or placebo intervention
2. Anabolic steroids with other intervention, where this is either
nutrition or exercises or both, versus no or placebo intervention
The second comparison will be analysed and presented separately
from the first, and main, comparison.
Types of outcome measures
Primary outcomes
The primary outcome will be function: for example, indepen-
dence in mobility and activities of daily living. Preference will be
given to validated, patient-reported outcome measures. Data on
adverse events including mortality, hospital readmission and com-
plications from the use of anabolic steroids will also be sought.
Secondary outcomes
Secondary outcomes will be patients’ perceived quality of life,
adherence and acceptability of the intervention, objective assess-
ments of body composition, nutritional indices, muscle strength
and use of resources such as length of hospital stay.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Bone, Joint and Muscle Trauma
Group SpecialisedRegister, theCochraneCentral Register of Con-
trolled Trials (The Cochrane Library current issue), MEDLINE
(1950 onwards), and EMBASE (1980 onwards). We will also
search Current Controlled Trials and the WHO international
Clinical Trials Registry Platform for ongoing and recently com-
pleted trials. We will apply no restrictions based on language or
publication status.
In MEDLINE (OvidSP), the subject specific search will be com-
binedwith theCochraneHighly Sensitive Search Strategy for iden-
tifying randomised trials in MEDLINE: sensitivity-maximizing
version (Lefebvre 2009) (Appendix 1), and will be modified for
use in other databases.
Searching other resources
The proceedings of the American Orthopaedic Trauma Associa-
tion’s annual meetings will be searched. This will be performed by
handsearching the table of contents of the meeting proceedings
(1996-2009). We will also search reference lists of relevant articles.
Data collection and analysis
Selection of studies
Two review authors (MC and VF) will independently screen
records identified from database searches for possible inclusion.
From the full text, trials which appear meet the selection criteria
will be selected for inclusion. Further information will be sought
from the trial authors if necessary. A third author (IDC) will mod-
erate any disagreement. Reasons for exclusionwill be documented.
Data extraction and management
Data extraction of the included studies will be completed, using
a piloted form, by combinations of two authors acting indepen-
dently. The data collected will include study design characteris-
tics, the study population, interventions, outcome measures, and
length of follow-up. Trial authors will be contacted for clarifica-
tion when necessary. Disagreements will be resolved by the other
review authors.
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Assessment of risk of bias in included studies
Combinations of two authors will independently assess risk of bias
using The Cochrane Collaboration’s ’Risk of bias’ tool (Higgins
2008a) (see Appendix 2). We will assess generation of allocation
sequence, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting, baseline imbalance, early stop-
ping, and other sources of bias. The risk of bias will be rated for
each domain and will be expressed as “Yes”, implying a low risk
of bias, “Unclear”, implying the risk of bias is unclear, or “No”,
implying a high risk of bias.
After piloting the ’Risk of bias’ tool for two trials, the review au-
thors responsible for data extraction will discuss any modifications
that may be required to enhance the assessment of risk of bias.
Measures of treatment effect
Results will be analysed at both short term (six months or less) and
longer term intervals. Risk ratios with 95% confidence intervals
will be calculated for dichotomous outcomes. Mean differences
with 95% confidence intervals will be calculated for continuous
outcomes.
Unit of analysis issues
The unit of randomisation in these trials is usually the individual
patient.However, wewill also consider randomised trialswhere the
unit of randomisation is another entity such as a hospital ward. If
possible, appropriate adjustments will be made before presenting
data from such trials if the trialists have not adjusted for clustering.
We will seek advice on the interpretation and presentation of the
results from such trials from the statistical editors of the Cochrane
Bone, Joint and Muscle Trauma Review Group.
Dealing with missing data
Where appropriate, we will perform intention-to-treat analysis to
include all people randomised. However where drop-outs have
been identified, the actual denominator of participants contribut-
ing data at the relevant outcome assessment will be used. We will
investigate the effect of drop-outs and exclusions by conducting
worst- and best-case scenario sensitivity analyses. The ’best-case’
scenario is when all participants with missing outcomes in the ex-
perimental intervention group are assigned a good outcome, and
all those with missing outcomes in the control intervention group
a bad outcome; the ’worst-case’ scenario is the converse. We will
be alert to potential mislabelling or non identification of standard
errors and standard deviations. Unless missing standard deviations
can be derived from confidence intervals, P values or standard er-
rors, we will not assume values in order to present these in the
analyses.
Assessment of heterogeneity
Heterogeneity will be assessed by visual inspection of the forest
plot (analysis) along with consideration of the chi² test for hetero-
geneity and the I² statistic (Higgins 2003).
Assessment of reporting biases
If sufficient data are available, we will attempt to assess publication
bias by preparing a funnel plot. We will also investigate selective
outcome reporting by comparing the study outcomes with those
routinely presented for similar studies and also by comparing the
methods section of trial reports with the results reported.
Data synthesis
If considered appropriate, results of comparable groups of trials
will be pooled. Initially we will use the fixed-effectmodel and 95%
confidence intervals. We will also consider using the random-ef-
fects model, especially where there is unexplained heterogeneity. It
is anticipated that we will pool data even if heterogeneity remains
high. For continuous outcomes, if outcomes are reported from
different scales or instruments assessing the same dimension, the
results will be pooled using standardised mean difference.Mindful
of unit of analysis issues, we will pool the data from cluster ran-
domised trials using the generic inverse variance. Studies that are
using anabolic steroids in conjunction with another intervention
such as nutritional supplementation will be analysed separately.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available, subgroup analysis will be performed
to determine whether primary outcomes vary according to gender
and route of administration.
Sensitivity analysis
Where possible, the review authorswill perform sensitivity analyses
to examine the effects of important sources of bias, such as whether
allocation was concealed, in the included studies.
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (OvidSP interface)
1 exp Femoral Fractures/
2 ((hip* or pertrochant* or intertrochant* or trochanteric or subtrochanteric or extracapsular* or ((femur* or femoral*) adj3 (neck or
proximal or head))) adj4 fracture*).mp.
3 1 or 2
4 exp Steroids/
5 exp Androgens/
6 exp Anabolic Agents/
7 (anabolic adj1 steroid*).mp.
8 (androgen* adj1 anabolic).mp.
9 (etiocholanolone or androst* or prasterone or stanolone or testosterone or methyltestosterone or metribolone or ethylestrenol or
fluoxymesterone or mesterolone or methandriol or methandrostenolone or methenolone or nandrolone or norethandrolone or oxan-
drolone or oxymetholone or stanozolol or trenbolone or amafolone or atromid or benorterone or boldenone or calusterone or danazol
or drostanolone or etiocholanone or mestanolone or mibolerone or testololactone or hydroxyandrost* or epiandrosterone or oxotestos-
terone or oxoandrostenedione).mp.
10 or/4-9
11 3 and 10
12 Randomized Controlled Trial.pt.
13 Controlled Clinical Trial.pt.
14 randomized.ab.
15 placebo.ab.
16 Drug Therapy.fs.
17 randomly.ab.
18 trial.ab.
19 groups.ab.
20 or/12-19
21 exp Animals/ not Humans/
22 20 not 21
23 11 and 22
Appendix 2. Risk of bias assessment tool
Domain Description Review authors’ judgement
Sequence generation Describe the method used to generate the
allocation sequence in sufficient detail to
allow an assessment of whether it should
produce comparable groups
Was the allocation sequence adequately
generated?
The judgement for Yes, Unclear orNowill
be based on criteria listed in Table 8.5.c in
the Handbook (Higgins 2008b)
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(Continued)
Allocation concealment Describe the method used to conceal the
allocation sequence in sufficient detail to
determinewhether intervention allocations
could have been foreseen in advance of, or
during, enrolment
Was allocation adequately concealed?
The judgement for Yes, Unclear orNowill
be based on criteria listed in Table 8.5.c in
the Handbook (Higgins 2008b)
Blinding of participants, personnel and
outcome assessors Assessments should be
made for each main outcome (or class of out-
comes).
Describe all measures used, if any, to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received. Provide any information re-
lating towhether the intendedblindingwas
effective
Was knowledge of the allocated inter-
vention adequately prevented during the
study?
The judgement for Yes, Unclear orNowill
be based on criteria listed in Table 8.5.c in
the Handbook (Higgins 2008b)
Incomplete outcome data Assessments
should be made for each main outcome (or
class of outcomes).
Describe the completeness of outcome data
for each main outcome, including attri-
tion and exclusions from the analysis. State
whether attrition and exclusions were re-
ported, the numbers in each intervention
group (compared with total randomised
participants), reasons for attrition/exclu-
sions where reported, and any re-inclusions
in analyses performedby the review authors
Were incomplete outcome data adequately
addressed?
The judgement for Yes, Unclear orNowill
be based on criteria listed in Table 8.5.c in
the Handbook (Higgins 2008b)
Selective outcome reporting State how the possibility of selective out-
come reportingwas examined by the review
authors, and what was found
Are reports of the study free of suggestion
of selective outcome reporting?
The judgement for Yes, Unclear orNowill
be based on criteria listed in Table 8.5.c in
the Handbook (Higgins 2008b)
Other sources of bias:
Baseline imbalance
State any important concerns about bias
not addressed in the other domains in the
tool
If particular questions/entries were pre-
specified in the review’s protocol, responses
should be provided for each question/entry
Prespecified source of bias
Was the study apparently free of problems
relating to imbalances in baseline charac-
teristics that could put it at a high risk of
bias?
Yes: There was no major imbalance in im-
portant baseline characteristics.
Unclear: The baseline characteristics were
not reported.
No: There was a major baseline imbalance
in at least one important baseline charac-
teristics
Other sources of bias:
Early stopping
State any important concerns about bias
not addressed in the other domains in the
tool
If particular questions/entries were pre-
specified in the review’s protocol, responses
should be provided for each question/entry
Prespecified source of bias
Was the study apparently free of problems
relating to early stopping that could put it
at a high risk of bias?
Yes: Sample size calculation was reported
and the trial was not stopped or the trial
was stopped early by formal
stopping rules at a point where the likeli-
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hood of observing an extreme intervention
effect due to chance was low.
Unclear: Sample size calculation was not
reported. It is unclear whether the trial was
stopped early or not.
No: The trial was stopped early due to
informal stopping rules or the trial was
stopped early by a formal stopping rule at a
point where the likelihood of observing an
extreme intervention effect due to chance
was high
Other sources of bias State any important concerns about bias
not addressed in the other domains in the
tool
Was the study apparently free of other prob-
lems that could put it at a high risk of bias?
Yes, Unclear or No.
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